Tag: pay for delay

Displaying 1 - 20 of 63 results.

Pages

The Federal Trade Commission is modernizing the process for filing agreements under the Medicare Prescription Drug, Modernization, and Improvements Act of 2003, or MMA, by requiring electronic filing instead of hard-copy submission. Starting June 17, 2019, MMA filings should be submitted to both...
Last week, Bureau of Competition staff published a report on filings received in fiscal year (FY) 2016 under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), the thirteenth such report since the MMA took effect in 2004.
A new Federal Trade Commission staff report found that, despite a considerable increase in the total number of final Hatch-Waxman patent settlements in FY 2016, significantly fewer settlements included the types of reverse payments that are likely to be anticompetitive.
The Federal Trade Commission announced its Opinion and Final Order against generic pharmaceutical company Impax Laboratories LLC.
The Federal Trade Commission has reached a settlement in FTC v. Actavis, the 2009 FTC case alleging that the brand-name drug company Solvay and three generic drug companies illegally agreed to restrict generic competition to Solvay’s branded testosterone-replacement drug AndroGel for nine years.
The Federal Trade Commission has reached a global settlement resolving pending claims in three separate federal court antitrust lawsuits involving subsidiaries of pharmaceutical manufacturer Teva Pharmaceuticals Industries Ltd. If approved by the various courts, the stipulated order will prohibit...
The Federal Trade Commission has filed an amicus brief in Takeda Pharmaceutical Co. v Zydus Pharmaceuticals (USA) Inc., which is a patent infringement case pending before the U.S. District Court for the District of New Jersey.
Brief of the Federal Trade Commission urging the District of New Jersey to reject argument that Hatch-Waxman patent infringement suits are categorically exempt from antitrust scrutiny as potential sham litigation, because the argument is contrary to the statutory text and case law...
In an Initial Decision announced on May 18, 2018, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in a complaint issued by the Federal Trade Commission against generic pharmaceutical company Impax Laboratories, Inc.
WHAT:The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics”. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr.
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements, according to a new FTC staff report.
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s...
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
In testimony presented to the U.S. House of Representatives’ Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to stop anticompetitive conduct in the pharmaceutical industry.
The Federal Trade Commission has approved the appointment of Quantic Regulatory Services, LLC as monitor in its case alleging that Endo Pharmaceuticals Inc. violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm.
The FTC's complaint alleges that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Lidoderm.  The agreement not to market an authorized generic – often...
The FTC's administrative complaint against Impax charges that in 2010, Impax and Endo Pharmaceuticals Inc. illegally agreed that Impax would not compete by marketing a generic version of Endo’s Opana ER until January 2013. In exchange, Endo paid Impax more than $112 million.Endo...

Pages